ConsensusCurrent

ASTCT — ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy

ASTCT, 2026

The updated grading consensus retains CRS/ICANS grading with clarifications and addresses IEC-HS, hematotoxicity, non-ICANS neurotoxicity and other emerging toxicities. It is a classification framework, not a stand-alone treatment guideline.

Expert opinionLow certainty

View source guideline

Clinical Context & Relevant Topics (1)

Disease Reference

Intracranial Hypertension & Cerebral Edema

Monro-Kellie doctrine, ICP waveforms (P2>P1, Lundberg A-waves), CPP targets (60–70 mmHg), herniation syndromes, and the 4-tier BTF management protocol.

View Topic Context →